Hirotsugu Kenmotsu

Shizuoka Cancer Center — Japan

Medicine · Health Sciences

41h-index7.9kcitations496works2.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(250), Lung Cancer Research Studies(133), Lung Cancer Diagnosis and Treatment(93), Cancer Genomics and Diagnostics(81), Gastrointestinal Tumor Research and Treatment(80)

Publications496 total

Weight change and Impact on prognosis in patients with Advanced Non-small Cell Lung Cancer with Concomitant diabetes mellitus treated with SGLT2 inhibitors
2026Open Access
IMpower010: 5‐Year Outcomes of Atezolizumab in Japanese Patients With Resected Stage IB–IIIA Non‐Small Cell Lung Cancer
Cancer Science·2025Open Access
Prognostic Impact of Weight Loss During First-Line Chemotherapy in Patients with Extensive-Disease Small Cell Lung Cancer
2025Open Access
Initial Patient Characteristics Associated With Ineligibility for Second‐Line Therapy After Progression on First‐Line Osimertinib in <scp> <i>EGFR</i> </scp> ‐Mutated Non‐Small Cell Lung Cancer
Thoracic Cancer·2025Open Access
1958P ONO-7475 phase I study: An open-label, uncontrolled study of ONO-7475 in combination with osimertinib in EGFR mutated advanced non-small cell lung cancer
Annals of Oncology·2025
Long-Term Safety and Effectiveness of Durvalumab in Unresectable Stage III NSCLC in Japan: A Multicenter Prospective Study (AYAME)
Journal of Thoracic Oncology·2025· 1 citedOpen Access
Allelic Imbalance and Chromothripsis Lead to Diversity in Japanese Tumor Genomes With Whole‐Genome Duplication
Cancer Science·2025Open Access
Association of FDG-PET/CT findings with adequate tissue samples for gene panel testing in transbronchial lung biopsy and endobronchial ultrasound-guided transbronchial needle aspiration
Respiratory Investigation·2025
Phase II study of afatinib for advanced non-small cell lung cancer with uncommon epidermal growth factor receptor mutations, including compound mutations detected by next-generation sequencing
International Journal of Clinical Oncology·2025· 1 cited
Current Status of Multimodal Therapy for Oligometastatic Disease, Induced Oligometastatic Disease, and Oligo-Progressive Disease in EGFR-Mutated Non-Small-Cell Lung Cancer
Cancers·2025Open Access
Current Status of Multimodal Therapy for Oligometastatic Disease, Induced Oligometastatic Disease and Oligo-Progressive Disease in EGFR-Mutated Non-Small Cell Lung Cancer
Preprints.org·2025Open Access
Effect of Cancer Cachexia on the Efficacy and Treatment Delivery of Chemotherapy in Older Patients With Advanced Small Cell Lung Cancer
Thoracic Cancer·2025· 1 citedOpen Access
Five-Year Survival Outcomes With Atezolizumab After Chemotherapy in Resected Stage IB-IIIA Non–Small Cell Lung Cancer (IMpower010): An Open-Label, Randomized, Phase III Trial
Journal of Clinical Oncology·2025· 22 citedOpen Access
Phase II trial of trametinib in patients with advanced solid tumors harboring genomic alterations in the MAPK pathway: Results from the BELIEVE trial (NCCH1901).
Journal of Clinical Oncology·2025
Localization of epidermal growth factor receptor-mutations using PNA:DNA probes in clinical specimens from patients with non-small cell lung cancer
Scientific Reports·2025Open Access
Longitudinal recurrence risk of adjuvant cytotoxic chemotherapy and gefitnib in resected lung cancer: A combined analysis of phase III studies
Lung Cancer·2025· 1 cited
Daily low-dose carboplatin or weekly carboplatin plus nab-paclitaxel for concurrent chemoradiotherapy in older patients with locally advanced non-small cell lung cancer (JCOG1914): A randomized phase 3 trial
SSRN Electronic Journal·2025Open Access
Frequency of ischemic cardiac events in patients receiving long-term multikinase inhibitor: A report of three cases
Asia-Pacific Journal of Oncology Nursing·2024· 2 citedOpen Access
Evaluation of whole genome sequencing utility in identifying driver alterations in cancer genome
Scientific Reports·2024· 3 citedOpen Access
Combination of Osimertinib and Vascular Endothelial Growth Factor Receptor Inhibitors for <i>EGFR</i> -Mutated Non–Small Cell Lung Cancer: Old or New Regimen?
Journal of Clinical Oncology·2024· 2 cited
page 1 of 25Next →

Frequent Co-authors

Toshiaki Takahashi(33), Haruyasu Murakami(27), Tateaki Naito(26), Masahiro Endo(26), Nobuyuki Yamamoto(26), Akira Ono(23), Kazushige Wakuda(16), Keita Mori(16), Takashi Nakajima(12), Takehito Shukuya(11), Tetsuhiko Taira(11), Yasuhiro Koh(10), Yasuhisa Ohde(10), Hiroaki Akamatsu(8), Shota Omori(8), Kyoichi Kaira(7), Hisao Imai(7), Terufumi Kato(7), Yukiko Nakamura(6), Asuka Tsuya(6)